Ralimetinib
- Generic Name
- Ralimetinib
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29FN6
- CAS Number
- 862505-00-8
- Unique Ingredient Identifier
- 73I34XW4HD
- Background
Ralimetinib has been used in trials studying the treatment of Postmenopausal, Advanced Cancer, Adult Glioblastoma, Fallopian Tube Cancer, and Metastatic Breast Cancer, among others.
A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
- Conditions
- Advanced CancerMetastatic CancerColorectal CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9
- Registration Number
- NCT02860780
- Locations
- 🇺🇸
Carolinas Medical Center, Charlotte, North Carolina, United States
🇺🇸Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
🇩🇪For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Köln, Germany
A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
- Conditions
- PostmenopausalMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- Centre Francois Baclesse
- Target Recruit Count
- 8
- Registration Number
- NCT02322853
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Centre Jean Perrin, Clermont -Ferrand, France
🇫🇷Centre Henri Becquerel, Rouen, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.